KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.

Tianshi Lu, Habib Hamidi, Mark A Socinski, Martin Reck, Federico Cappuzzo, Fabrice Barlesi, Robert M Jotte, Sören Müller, Aditi Qamra, Assaf Amitai, Xiangnan Guan, Eloisa Fuentes, Hartmut Koeppen, Jennifer M Giltnane, David S Shames, Marcus Ballinger, Meng Xiao He, Yulei Wang, Minu K Srivastava, Barzin Y Nabet

Nat Commun 17(1) 122

PMID41339316
PMCIDPMC12775477
DOI10.1038/s41467-025-66803-8
发表日期2025-12-03
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

The phase 3 IMpower150 trial in treatment-naïve patients with metastatic non-small-cell lung cancer (NSCLC) demonstrates significantly longer progression-free (PFS) and overall survival (OS) with first-line atezolizumab (anti-PD-L1)-bevacizumab (anti-VEGF)-carboplatin-paclitaxel (ABCP) than with bevacizumab-carboplatin-paclitaxel (BCP). We characterise four molecular NSCLC subtypes identified by unsupervised clustering of transcriptomes of 564 pre-treatment primary tumour samples from IMpower150 using non-negative matrix factorization (NMF1-4). Each subtype has distinct tumour PD-L1 expression levels, epithelial characteristics, immune composition, and treatment outcomes. Both NMF2 (enriched in tumour proliferation signal, macrophages, and monocytes) and NMF4 (enriched in B cells and T cells) have elevated tumour PD-L1 expression. Of these two, only NMF4 demonstrates PFS and OS benefits with ABCP versus either BCP or atezolizumab-carboplatin-paclitaxel (ACP). Patients with NMF1 (enriched in basal and squamous-like cells) have improved outcomes on ABCP compared with ACP or BCP; those with NMF3 (enriched in adenocarcinoma signatures) show similar outcomes among treatments. These insights could help inform individualised first-line treatment for metastatic NSCLC.

KM 提取结果

1 个 Figure · 11 个 KM 面板

进入结果中心
KM Figure11 个面板

Fig. 3

Fig. 3. Association between clinical outcomes with atezolizumab-bevacizumab-chemotherapy combinations and NMF subtype in IMpower150. a PFS in each treatment arm by NMF subtype. The forest plot shows the PFS HRs for ABCP vs BCP for each subtype. b OS in each treatment arm by NMF subtype. The forest plot shows the OS HRs for ABCP vs BCP. c Comparison of PFS across NMF subtypes by treatment. d Comparison of PFS (top 3 panels) and OS (bottom 3 panels) with ABCP vs BCP in NMF2 and NMF4 subtypes by PD-L1 level: PD-L1–high (tumour proportion score ≥ 50% by SP263 IHC assay), PD-L1–low (1%-49%) and PD-L1–negative (< 1%). Data in the ACP arm were not substantially different from those in the BCP arm and are not shown in the graphs to aid visualization. e Results of the multivariate analysis evaluating the association between the outcomes (PFS: left panel, and OS: right panel) and multiple factors on the ABCP arm. These factors include NMF subtypes, PD-L1 levels, tumor mutation burden, STK11/KEAP1 mutational status, and smoking history. Source data are provided as a Source Data file. For the forest plots in a,b , e , each row represents a different predictor variable, with the point estimates and 95% CIs for the HRs displayed as squares and horizontal error bars, respectively. The vertical dashed line represents the line of no effect (HR = 1.0). Variables with confidence intervals that do not cross this line are considered statistically significant. For the survival analyses in a , b , e , the log-rank test was used to compare Kaplan-Meier survival curves. Cox proportional hazards regression models were used to generate hazard ratios and 95% confidence intervals. Multivariable Cox proportional hazards regression models were used to compare the interdependence of distinct biomarkers for prediction of OS benefit. ABCP atezolizumab plus bevacizumab plus carboplatin-paclitaxel, ACP atezolizumab plus carboplatin-paclitaxel, BCP bevacizumab plus carboplatin-paclitaxel, NE not estimable.

A

PFS

Fig. 3 · Panel A

quality_warning 待 EXE 对齐 预期 12 条 已提取 7 条

Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 12 条,实际恢复 7 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

OS

Fig. 3 · Panel B

quality_warning 待 EXE 对齐 预期 12 条 已提取 3 条

Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 12 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

PFS

Fig. 3 · Panel C

quality_warning 待 EXE 对齐 预期 5 条 已提取 3 条

Panel C 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 5 条,实际恢复 3 条曲线 2:extreme upward reversal曲线 4:off origin start曲线 4:extreme upward reversal
查看结果
C_4

PFS

Fig. 3 · Panel C_4

quality_warning 待 EXE 对齐 预期 5 条 已提取 1 条

Panel C_4 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 5 条,实际恢复 1 条曲线 1:extreme jump曲线 1:off origin start曲线 1:extreme upward reversal
查看结果
C_5

PFS

Fig. 3 · Panel C_5

quality_warning 待 EXE 对齐 预期 5 条 已提取 4 条

Panel C_5 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线交叉次数异常,需检查跨图跳线或误跟踪曲线缺失:预期 5 条,实际恢复 4 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

PFS

Fig. 3 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D_7

PFS

Fig. 3 · Panel D_7

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D_7 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
D_8

PFS

Fig. 3 · Panel D_8

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D_8 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D_9

OS

Fig. 3 · Panel D_9

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D_9 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D_10

OS

Fig. 3 · Panel D_10

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D_10 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D_11

OS

Fig. 3 · Panel D_11

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D_11 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:flat topline artifact
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. Transcriptional classification reveals four subtypes of non-squamous NSCLC with distinct biologies. a RNA-sequencing data from NSCLC tumour samples from 564 patients in the IMpower150 trial were grouped into the four molecular subtypes shown in the consensus matrix, based on genes with the highest expression variance, using non-negative matrix factorization. Heatmap summarizing consensus clustering of samples factorized via NMF (k = 4; for details see Methods), with each sample represented in one row/column. Consensus values (the fraction of times of every pair of samples clustered together across multiple iterations of factorization) are represented as red when two samples always cluster together and purple when two samples never cluster together. b Heatmap for gene expression signatures of various immune cell types and cancer-related pathways in each NMF subtype, compared with all other patients in IMpower150 (left panel). The dot heatmap (right panel) shows the summarized gene signature enrichment or diminution in each NMF subtype. c Heatmap of gene signature enrichment or diminution for B cells, myeloid cells, stroma cells, and T effector cells by NMF subtype. d Proportions of patients whose tumour samples were well differentiated, moderately differentiated, or undifferentiated. e Proportions of patients whose tumour samples had PD-L1–positive (> 50% using the SP263 immunohistochemistry assay), PD-L1–low (1-49%), and PD-L1–negative (< 1%) protein expression by NMF subtype. f Distribution of The Cancer Genome Atlas lung adenocarcinoma (LUAD) subtypes (left panel) and of LUAD subtypes defined by Roh et al. (right panel) among NMF subtypes. Source data are provided as a Source Data file. cDC1 conventional type 1 dendritic cell, cDC2 conventional type 2 dendritic cell, EMT epithelial-mesenchymal transition, DC mature mature dendritic cell, NK cell natural killer cell, pDC plasmacytoid dendritic cell, sc.foll.b follicular B cell profiled from single-cell dataset, sc.GC.b germinal centre B cell profiled from single-cell dataset, sc.plasma plasma cell profiled from single-cell dataset.
非 KM Figure
Fig. 2Fig. 2. Landscape of somatic mutations in the NMF molecular subtypes. a Oncoplot of genes that had mutations and copy number variations in ≥ 2% of 261 tumour samples used in whole-exome sequencing analyses. b Oncoplots for the four NMF subtypes, showing genes altered in ≥ 10% of samples in the same order as in Fig. 2a. c FDR-adjusted P values from a Pearson’s χ 2 test are reported for comparisons of mutations in each indicated gene among samples. d Percentage of NSCLC samples carrying variations in each gene by NMF subtype. The proportions of each molecular subtype with available whole exome sequencing data were 37 NMF1 samples (35.9%), 84 NMF2 samples (46.2%), 73 NMF3 samples (46.8%), and 65 NMF4 samples (54.6%). e Tumour mutation burden (TMB) in each NMF subtype. The lower and upper hinges in the box plot correspond to the first and third quartiles. The upper whisker extends from the hinge to the largest value no further than 1.5× IQR from the hinge (where IQR is the interquartile range, or distance between the first and third quartiles). The lower whisker extends from the hinge to the smallest value at most 1.5× IQR of the hinge. There were 37 samples in NMF1, 85 samples in NMF2, 73 samples in NMF3, and 65 samples in NMF4. Source data are provided as a Source Data file. Two-sided t-test was used for pairwise comparison. P values were 0.128 (NMF2 vs NMF4), 0.6238 (NMF3 vs NMF1), 0.6907 (NMF4 vs NMF1), 0.0038 (NMF3 vs NMF2), 0.0016 (NMF4 vs NMF2), 0.9396 (NMF4 vs NMF3). * P < 0.05; ** P < 0.01; *** P < 0.001.
非 KM Figure
Fig. 4Fig. 4. NSCLC subtypes have different stromal pathologic features and treatment outcomes. a Distribution of lymphocyte and plasma cell density in the cancer stroma and cancer epithelium by NMF subtype. * P < 0.05; ** P < 0.01; *** P < 0.001. P-values can be found in the Source Data. The lower and upper hinges in the box plot correspond to the first and third quartiles. The upper whisker extends from the hinge to the largest value no further than 1.5× IQR from the hinge (where IQR is the interquartile range, or distance between the first and third quartiles). The lower whisker extends from the hinge to the smallest value at most 1.5× IQR of the hinge. Two-sided t-test was used for the statistical test. b Scatterplots of plasma cell and lymphocyte cell densities in each NMF subtype. Each dot indicates one sample. Samples are grouped by the median of plasma cell and lymphocyte density. Red: plasma cell-high, lymphocyte-high; orange: plasma cell-low, lymphocyte-high; green: plasma cell-high lymphocyte-low; blue: plasma cell-low, lymphocyte-low. The percentages within each quartile indicate the fraction of samples within each group. c Forest plots show the median PFS and HR by stromal cell density ratio for patients in IMpower150 who received ABCP compared with BCP (left panel) and ACP compared with BCP (right panel). There were 74 samples in the HH group, 24 in the LH group, 20 in the HL group, and 78 in the LL group in the ABCP arm; 83 samples in the HH group, 18 in the LH group, 21 in the HL group, and 67 in the LL group in the BCP arm; 54 samples in the HH group, 24 in the LH group, 25 in the HL group, and 69 in the LL group in the ACP arm. d Proportions of tertiary lymphoid structures (TLS) in each NMF subtype. Sample numbers were NMF1: n = 106; NMF2: n = 187; NMF3: n = 169; NMF4: n = 124. Source data are provided as a Source Data file. ABCP atezolizumab plus bevacizumab plus carboplatin-paclitaxel, ACP atezolizumab plus carboplatin-paclitaxel, BCP bevacizumab plus carboplatin-paclitaxel, HH high-high, LH low-high, HL high-low, LL low-low.
非 KM Figure